Catalog No.
VVV04301
Species reactivity
Lassa virus (strain Mouse/Sierra Leone/Josiah/1976) (LASV)
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Target
Pre-glycoprotein polyprotein GP complex, Pre-GP-C, Stable signal peptide, SSP, Glycoprotein G1, GP1, Glycoprotein G2, GP2, GPC, GP-C
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P08669
Applications
ELISA, Neutralization
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
LAVA01
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa fever., PMID:40367816
Mapping the antibody response to Lassa virus vaccination of non-human primates., PMID:40168843
Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials., PMID:40157130
Structure-guided design of a prefusion GPC trimer induces neutralizing responses against LASV., PMID:39987102
Conformational ensemble-based framework enables rapid development of Lassa virus vaccine candidates., PMID:39605488
Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability., PMID:38177144
Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies., PMID:37209096
Deletion of the first glycosylation site promotes Lassa virus glycoprotein-mediated membrane fusion., PMID:37059226
Holding it together: Nanoparticle stabilization of LASV trimer., PMID:36521442
A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus., PMID:36288283
Neutralizing Antibodies against Lassa Virus Lineage I., PMID:35730904
Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies., PMID:35613585
Construction and Immunological Evaluation of an Adenoviral Vector-Based Vaccine Candidate for Lassa Fever., PMID:33804206
Effects of N-Linked Glycan on Lassa Virus Envelope Glycoprotein Cleavage, Infectivity, and Immune Response., PMID:33689141
ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge., PMID:33654106
Identification of Common CD8+ T Cell Epitopes from Lassa Fever Survivors in Nigeria and Sierra Leone., PMID:32269122
A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge., PMID:31466243
Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization., PMID:31398326
Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques., PMID:31071008
Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever., PMID:30310067
Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development., PMID:29581897
Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins., PMID:29287681
An LASV GPC pseudotyped virus based reporter system enables evaluation of vaccines in mice under non-BSL-4 conditions., PMID:28797730
Shedding of soluble glycoprotein 1 detected during acute Lassa virus infection in human subjects., PMID:21062490
Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever., PMID:20961433
Uncoupling GP1 and GP2 expression in the Lassa virus glycoprotein complex: implications for GP1 ectodomain shedding., PMID:19105844
Identification of protective Lassa virus epitopes that are restricted by HLA-A2., PMID:16912286
A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins., PMID:16412488
For research use only. Not for human or drug use.
